Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scientists have developed a first-of-its-kind mass spectrometry method for vaccine authenticity screening using machine learning. The method repurposes clinical mass spectrometers already present in hospitals worldwide, making the approach feasible for global supply chain monitoring. The discovery offers an effective solution to the rise in substandard and counterfeit vaccines threatening public health.

An African child receiving a vaccine via injection in the arm © © Curt Carnemark, World Bank

Research published today in the Nature portfolio journal npj Vaccines and led by University of Oxford researchers describes a new method capable of distinguishing authentic and falsified vaccines using machine learning analysis of mass spectral data. The method proved effective in differentiating between a range of authentic and ‘faked’ vaccines previously found to have entered supply chains.

A key benefit of the novel method is that it uses clinical mass spectrometers already distributed globally for medical diagnostics, giving it the potential to address the urgent need for more effective global vaccine supply chain screening.

The global population is increasingly reliant on vaccines to maintain population health with billions of doses used annually in immunisation programs worldwide. The vast majority of vaccines are of excellent quality. However, a rise in substandard and falsified vaccines threaten global public health. Besides failing to treat the disease for which they were intended, these can have serious health consequences, including death, and reduce confidence in vaccines. Unfortunately, there is currently no global infrastructure in place to monitor supply chains using screening methods developed to identify ineffective vaccines.

In this new study, researchers developed and validated a method that is able to distinguish authentic and falsified vaccines using instruments developed for identifying bacteria in hospital microbiology laboratories. The method is based on matrix-assisted laser desorption/ionisation-mass spectrometry (MALDI-MS), a technique used to identify the components of a sample by giving the constituent molecules a charge then separating them.*   The MALDI-MS analysis is then combined with open-source machine learning. This provides a reliable multi-component model which can differentiate authentic and falsified vaccines, and is not reliant on a single marker or chemical constituent.

The method successfully distinguished between a range of genuine vaccines – including for influenza (flu), hepatitis B virus, and meningococcal disease – and solutions commonly used in falsified vaccines, such as sodium chloride.

The results provide a proof-of-concept method that could be scaled to address the urgent need for global vaccine supply chain screening.

Professor James McCullagh, study co-leader and Professor of Biological Chemistry in the Department of Chemistry, said: 'We are thrilled to see the method’s effectiveness and its potential for deployment into real-world vaccine authenticity screening. This is an important milestone for The Vaccine Identity Evaluation (VIE) consortium which focusses on the development and evaluation of innovative devices for detecting falsified and substandard vaccines, supported by multiple research partners including the World Health Organization (WHO), medicine regulatory authorities and vaccine manufacturers.'

Co-author Professor Nicole Zitzmann, Professor of Virology in the Department of Biochemistry, said: 'This latest research will bring the world community one step closer to being able to tell apart falsified, ineffective vaccines from the real thing, making us all safer. It has been a tremendous collaborative effort, with everyone having this same important goal in mind.'

Co-author Professor Paul Newton, Professor of Tropical Medicine at NDM's Centre for Tropical Medicine and Global Health, said: 'This innovative research provides compelling evidence that MALDI mass spectrometry techniques could be used in accessible systems for screening for vaccine falsification globally, especially in centres with hospital microbiology laboratories,  enhancing public health and confidence in vaccines.'

Please also see the news story from Kavli Institute for Nanoscience Discovery on this work

Read the full paper on the npj Vaccines website: https://www.nature.com/articles/s41541-024-00946-5

Similar stories

KEMRI renews collaboration with Wellcome Trust and University of Oxford

The Kenya Medical Research Institute (KEMRI) has signed a seven-year Memorandum of Agreement with Wellcome Trust, a UK charitable organization, and the University of Oxford, on Wednesday 27 November 2024, at the KEMRI Headquarters, Nairobi. Under this collaboration, Wellcome has awarded GBP 91 million (KES 15 billion) to support research over the next 7 years.